Emmet Kelly: We've got a few minutes
However, concerns remain about weight regain after stopping AOMs
GLP-1 drugs, including Wegovy and similar medications, mimic hormones that regulate appetite and blood sugar, helping patients feel full and eat less
2009), while stimulating HSC proliferation and transformation into myofibroblasts (Ioannou et al
When tanycytic transcytosis was blocked either by preventing vesicle release or by eliminating GLP-1 receptors from tanycytes the ability of liraglutide to suppress appetite was abolished
The patient has established cardiovascular disease with a documented history of at least one of the following: A) Previous myocardial infarction (MI) B) Previous stroke C) Symptomatic peripheral arterial disease (PAD), evidenced by one of the following: Intermittent claudication with an ankle-brachial index (ABI) less than 0.85 at rest Peripheral arterial revascularization procedure Amputation due to atherosclerotic disease D) Prior revascularization, such as coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), or angioplasty, and